Phase I Clinical Trial of the Wee1 inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase 1 Consortium Report (ADVL1312).

CONCLUSION: Adavosertib (85 mg/m2) in combination with irinotecan (90 mg/m2) administered orally for 5 days was the maximum tolerated dose in children and adolescents with solid and CNS tumors. PMID: 31857431 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31857431?dopt=Abstract

Source: Clinical Cancer Research - December 18, 2019 Category: Cancer & Oncology Authors: Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, Pawel BR, Maris JM, Haas-Kogan DA, Voss SD, Berg SL, Reid JM, Fox E, Weigel BJ Tags: Clin Cancer Res Source Type: research